




PHARMACEUTICAL 2018

Ra Pharmaceuticals Inc.
Rank 136 of 342





PHARMACEUTICAL 2018

Ra Pharmaceuticals Inc.
Rank 136 of 342

The relative strengths and weaknesses of Ra Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ra Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 85% points. The greatest weakness of Ra Pharmaceuticals Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 57% points.

The company's Economic Capital Ratio, given in the ranking table, is 142%, being 96% points above the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	72,877
Cost of Goods Sold	0
Intangible Assets	380
Liabilities, Current	8,614
Liabilities, Non-Current	0
Other Assets	1,334
Other Compr. Net Income	0
Other Expenses	-19
Other Liabilities	2,399
Other Net Income	571
Other Revenues	0
Property and Equipment	5,606
Research and Development	45,251
Selling, General and Administrative Expense	9,778

Output Variable	Value in 1000 USD
Assets	80,197
Liabilities	11,013
Expenses	55,010
Revenues	0
Stockholders Equity	69,184
Net Income	-54,439
Comprehensive Net Income	-54,439
Economic Capital Ratio	142%